Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280956 · ClinicalTrials.gov registry record · Phase 4
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
A Phase 4 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,000
- Enrollment target
NCT00280956: Completed Phase 4 study, sponsored by Biogen.
NCT00280956 is a Phase 4 study that has completed, run by Biogen. The registered enrollment target is 2,000 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (286% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00280956, a Phase 4 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
What the finished NCT00280956 record still lists
NCT00280956 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (286% higher).
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT00280956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00280956 about?
NCT00280956 is a clinical study titled "Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease". The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
What is the current status of trial NCT00280956?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,000 participants. The study started on 2002-07. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00280956?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00280956?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00280956's enrollment target sits among peer trials
2,000 37th of 2000 higher than 1,958 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia